Nightingale Health Oyj (FRA:7XE)

Germany flag Germany · Delayed Price · Currency is EUR
0.7600
+0.0080 (1.06%)
Last updated: May 26, 2026, 8:04 AM CET
Market Cap52.51M -69.9%
Revenue (ttm)4.80M -3.2%
Net Income-19.07M
EPS-0.32
Shares Out n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Open0.7600
Previous Close0.7520
Day's Range0.7600 - 0.7600
52-Week Range0.7500 - 2.8400
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateJun 3, 2026

About Nightingale Health Oyj

Nightingale Health Oyj, a health technology company, offers advanced health check that detects disease risks in Finland, the United Kingdom, rest of Europe, the United States, and internationally. The company’s Health Check that detects the risks associated with various common chronic diseases from a single blood sample; and Remote Health Check where health check done remotely. It also offers blood analysis, self collection kits, urine analysis, and biomarkers services. It provides its services to research programs, universities, and healthcare... [Read more]

Industry Medical Laboratories
Founded 2002
Employees 103
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 7XE

Financial Performance

In fiscal year 2025, Nightingale Health Oyj's revenue was 4.69 million, an increase of 7.69% compared to the previous year's 4.36 million. Losses were -18.46 million, 5.71% more than in 2024.

Financial Statements

News

Nightingale Health Oyj Earnings Call Transcript: H1 2026

Revenue grew 4% in H1, with strong order book and pilots supporting a reiterated 50% full-year growth target. Major partnerships expanded, new contracts secured, and US market entry advanced with the New York lab permit. H2 focus is on targeted sales and commercial scaling.

2 months ago - Transcripts

Nightingale Health Oyj Quarterly report: H1 2026

Nightingale Health Oyj has published its H1 2026 quarterly earnings report on March 5, 2026.

2 months ago - Filings

Nightingale Health Oyj Slides: H1 2026

Nightingale Health Oyj has posted slides in relation to its H1 2026 quarterly earnings report, which was published on March 5, 2026.

2 months ago - Filings

Nightingale Health Oyj Earnings Call Transcript: H2 2025

Revenue grew 8% year-over-year to €4.7 million, with strong liquidity and no debt. Major milestones included a public sector deal in Finland, U.S. lab expansion, and a new multi-omics research contract. The outlook targets at least 50% revenue growth this year.

8 months ago - Transcripts

Nightingale Health Oyj Annual report: H2 2025

Nightingale Health Oyj has published its H2 2025 annual report on September 18, 2025.

8 months ago - Filings

Nightingale Health Oyj Quarterly report: H2 2025

Nightingale Health Oyj has published its H2 2025 quarterly earnings report on September 18, 2025.

8 months ago - Filings